drugset / Trial / NCT02334293

Omegaven® as Parenteral Nutrition

NCT02334293

Unknown 25 enrolled Carle Foundation Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if a fat emulsion comprised of omega-3 fatty acids, Omegaven, would be beneficial in the management of steatotic liver injury in parenteral nutrition (PN) by its inhibition of de novo lipogenesis, the reduction of arachidonic acid-derived inflammatory mediators, prevention of essential fatty acid deficiency through the presence of small amounts of arachidonic acid, and improved clearance of lipids from the serum.

Timeline

Start
2013-10
Primary completion
2017-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Omegaven Other / unclassified

Indications